Get the Stockscreener App
557.73
1.22%
-6.90
After Hours:
558.63
0.90
+0.16%
Regeneron Pharmaceuticals Inc stock is traded at $557.73, with a volume of 1.34M.
It is down -1.22% in the last 24 hours and down -0.41% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$564.63
Open:
$551.5
24h Volume:
1.34M
Relative Volume:
1.30
Market Cap:
$58.10B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.05
EPS:
39.6877
Net Cash Flow:
$3.56B
1W Performance:
-4.74%
1M Performance:
-0.41%
6M Performance:
+0.64%
1Y Performance:
-45.09%
1-Day Range:
$541.00
$563.77
1-Week Range:
$541.00
$605.00
52-Week Range:
$476.49
$1,024.36
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Citigroup Maintains "Buy" Rating on REGN, Raises Price Target to $660 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Weekly Gains Summary & High Conviction Buy Zone Picks - newser.com
Regeneron plans FDA filing based on latest DB-OTO data - The Pharma Letter
Using data filters to optimize entry into Regeneron Pharmaceuticals Inc.Gap Up & Weekly Setup with High ROI Potential - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down on Analyst Downgrade - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge - Yahoo Finance
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could 'Transform Patients’ Lives' - BioSpace
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss - Zacks Investment Research
Cell And Gene Therapy For Multiple Myeloma Market Positioned - openPR.com
Biosimilar Fights Regeneron Bid To Block Eye Treatment - Law360
A New Gene Therapy for Deafness Looks Promising - Bloomberg.com
Cwm LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today - MSN
Cantor Fitzgerald Brokers Raise Earnings Estimates for REGN - MarketBeat
Regeneron (REGN) Gene Therapy Shows Promising Results for Geneti - GuruFocus
How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise? - Yahoo Finance
Regeneron Pharma Reports Promising Results For DB-OTO Gene Therapy In Genetic Hearing Loss - Nasdaq
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy - BioPharma Dive
Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss - MarketScreener
GW Henssler & Associates Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meritage Portfolio Management Acquires Shares of 11,455 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Hobbs Group Advisors LLC - MarketBeat
606 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Clear Creek Financial Management LLC - MarketBeat
Prime Capital Investment Advisors LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN) Is Up After FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CSCC - simplywall.st
Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
JB Capital LLC Invests $3.62 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aberdeen Group plc Has $106.97 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Lmcg Investments LLC - MarketBeat
Callan Family Office LLC Has $3.17 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Morgan Stanley Lowers Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals Inc. stock daily chart insightsRisk Management & Precise Buy Zone Tips - newser.com
Is Regeneron at a Turning Point After 43% Drop and FDA Eye Drug Approval News? - simplywall.st
Will Regeneron Pharmaceuticals Inc. continue its uptrend2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock? - Forbes
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Sysmex (SSMXF) - The Globe and Mail
Can you recover from losses in Regeneron Pharmaceuticals Inc.July 2025 Macro Moves & High Conviction Buy Zone Alerts - newser.com
Can Regeneron Pharmaceuticals Inc. (RGO) stock deliver consistent EPS growthPortfolio Risk Summary & Verified Entry Point Signals - newser.com
Leo Wealth LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Forecasting Regeneron Pharmaceuticals Inc. price range with options dataEntry Point & Daily Oversold Bounce Ideas - newser.com
How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks? - MSN
Libtayo’s CSCC Label Expansion Broadens Practitioner Base - insights.citeline.com
Regeneron Pharmaceuticals Hits Day Low of $561 Amid Price Pressure - Markets Mojo
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients - Benzinga
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ - Stocktwits
Regeneron, needing a turnaround, gains new use for cancer drug - BioPharma Dive
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo - The Globe and Mail
New FDA approval for Libtayo - The Pharma Letter
8,976 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Bar Harbor Wealth Management - MarketBeat
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery - Yahoo
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):